CICN - Université Catholique de Louvain
Louvain-la-Neuve, Belgium
NCT Number: NCT05199545
The objective of the study is to compare the effect of a 6-week supplementation with a dietary supplement based on plant extracts to the effect of placebo, in patients with a moderate depressive episode (F32.1 by ICD10 definition) and with moderate symptoms (score HAM-D ≥ 16 and ≤ 23).
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Louvain-la-Neuve, Belgium
Longitudinal, comparative, randomized, placebo-controlled interventional study in 2 parallel groups, double-blind, monocentre, aimed at demonstrating the superiority of the combination of plants over placebo on depressive symptoms.
Each patient will be followed for a maximum of 6 weeks, with 3 visits to the doctor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
Placebo of the dietary supplement
Time frame: 42 days
Score HAM-D at D42, adjusted to the value at D0 minimum = 0 and maximum = 53 higher score means a worse outcome
Time frame: 42 days
Evolution of score HAM-D between D0, D21 and D42
Time frame: 42 days
Evolution of sub-scores HAM-D between D0, D21 and D42
Time frame: 21 days
HAM-D score showing a decrease of ≥ 3 points compared to D0
Time frame: 42 days
HAM-D score showing a decrease of ≥ 3 points compared to D0
Time frame: 21 days
HAM-D score showing a decrease of ≥ 5 points compared to D0
Time frame: 42 days
HAM-D score showing a decrease of ≥ 5 points compared to D0
Time frame: 21 days
score HAM-D ≤ 7
Time frame: 42 days
score HAM-D ≤ 7
Time frame: 42 days
Evolution of sub-scores HADS-D between D0, D21 and D42 minimum = 0 and maximum = 21 higher score means a worse outcome
Time frame: 42 days
Evolution of sub-scores HADS-A between D0, D21 and D42 minimum = 0 and maximum = 21 higher score means a worse outcome
Time frame: 42 days
Evolution of Clinical Global Impression-Severity (CGI-S) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome
Time frame: 42 days
Evolution of Clinical Global Impression-Improvement (CGI-I) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome
Time frame: 42 days
Evolution of Patient Global Impression-Improvement (PGI-I) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome
Time frame: 42 days
Number and type of adverse events
Time frame: 42 days
Evolution of Sheehan Disability Score (SDS) between D0, D21 and D42 minimum = 0 and maximum = 44 higher score means a worse outcome
Time frame: 21 days
5-point Likert scale (minimum = 1 and maximum = 5) higher score means a better satisfaction
Time frame: 42 days
5-point Likert scale
Time frame: 42 days
Number of intercurrent visits
Time frame: 42 days
Number and type of concomitant drugs
Time frame: 21 days
Counting of therapeutic units at D21
Time frame: 42 days
Counting of therapeutic units at D42
Time frame: 42 days
Rate of participants on the same dietary supplement, antidepressant medication, other or without treatment at the end of the study
Larena SAS
Industry
Acronym: ROSADE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06965959
Aging, Behavior
Sivas, Central, Turkey (Türkiye)
View Trial DetailsNCT07005960
Anxiety, Anxiety Disorders
Çeşme, İzmir, Turkey (Türkiye)
View Trial DetailsNCT07620483
Behavior, Cognitive Fusion
Cali, Valle del Cauca Department, Colombia
View Trial DetailsNCT06352801
ADHD, Attention Deficit Disorder with Hyperactivity
Hong Kong
View Trial Details